Insight into pimecrolimus experience in seborrheic dermatitis: Close follow-up with exact mean cure and remission times and side-effect profile

2009 ◽  
Vol 20 (4) ◽  
pp. 198-202 ◽  
Author(s):  
Semih Tatlican ◽  
Cemile Eren ◽  
Fatma Eskioglu
Keyword(s):  
Side Effect ◽  
Seborrheic Dermatitis ◽  
Side Effect Profile ◽  
Insight Into

Safety and Efficacy Results of a Randomized Trial Comparing Adjuvant Toremifene and Tamoxifen in Postmenopausal Patients With Node-Positive Breast Cancer

2000 ◽  
Vol 18 (20) ◽  
pp. 3487-3494 ◽  
Author(s):  
Kaija Holli ◽  
Ritva Valavaara ◽  
Guillermo Blanco ◽  
Vesa Kataja ◽  
Päivi Hietanen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effect ◽  
Cancer Recurrence ◽  
Breast Cancer Recurrence ◽  
Side Effect Profile ◽  
Treatment Groups ◽  
Node Positive ◽  
Er Positive ◽  
The Mean

PURPOSE: In this multicenter trial, toremifene 40 mg/d was compared with tamoxifen 20 mg/d, both given orally for 3 years to postmenopausal, axillary node–positive women after breast surgery. PATIENTS AND METHODS: The first 899 patients (toremifene, n = 459; tamoxifen, n = 440) of the total of 1,480 patients accrued to the trial were included in this scheduled safety analysis. The mean follow-up time was 3.4 years. RESULTS: The two treatment groups were well balanced with respect to patient and disease characteristics. The subjective side-effect profile was similar in both treatment groups. Slightly more vascular complications (deep vein thromboses, cerebrovascular events, and pulmonary embolisms) were seen among tamoxifen-treated patients (5.9%) as compared with toremifene-treated patients (3.5%) (P = .11), whereas bone fractures (P = .09) and vaginal leukorrhea (P = .05) were more common in the toremifene group. The number of subsequent second cancers was similar. The breast cancer recurrence rate was 23.1% (n = 106) in the toremifene group and 26.1% (n = 115) in the tamoxifen group (P = .31). When only patients with estrogen receptor (ER)–positive cancer were considered (n = 556), the risk for breast cancer recurrence was nonsignificantly lower among the toremifene-treated women, with a hazards ratio of 0.74 (90% confidence interval, 0.52 to 1.04; P = .14). The mean time to breast cancer recurrence and overall survival were similar in both groups. CONCLUSION: The side-effect profile of toremifene resembles that of tamoxifen. The efficacy of toremifene seems to be no less than that of tamoxifen. The trend for fewer breast cancer recurrences in the ER-positive subgroup is encouraging, but a longer follow-up is needed to confirm this.

MEDICAL METHODS OF ABORTION (MMA), HOW SAFE?

2021 ◽  
pp. 51-52
Author(s):  
Anita Pathak
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Unsafe Abortion ◽  
Self Administration ◽  
Mortality And Morbidity ◽  
Incomplete Abortion ◽  
Referral Practices ◽  
Maternal Mortality And Morbidity ◽  
Insight Into

Unsafe abortion is important and preventable cause of maternal mortality and morbidity. Medical method of abortion is a safe efcient and affordable method of abortion. However incomplete abortion is known side effect. An insight into the referral practices in cases of incomplete abortion following medical method of abortion will give an idea of the safety prole of medical methods of abortion. 150 women with incomplete abortion following medical method of abortion were administered a questionnaire which included information regarding onset of bleeding, treatment received, use of medication for abortion, its prescription, and administration. 90% of incomplete abortion following medical method of abortion were due to self-administration or prescription by unregistered practitioners, lack of examinations and lack of follow up. Complications such as collapse, blood requirement and fever were signicantly higher in these patients. The side effects of incomplete abortion following medical method of abortion can be minimized by following the standard guidelines.

scholarly journals Pseudotumor of the Larynx: A Previously Unreported Side Effect of Apremilast

2020 ◽  
Vol 12 (3) ◽  
pp. 275-281
Author(s):  
Eleftherios Ntouniadakis ◽  
Fredrik Landström
Keyword(s):  
Plaque Psoriasis ◽  
Side Effect ◽  
Side Effect Profile ◽  
Off Label ◽  
Psoriasis Arthritis ◽  
First Case ◽  
Disease Modifying ◽  
Rheumatic Drug

Apremilast (Otezla®) is a relatively novel orally administered non-biologic disease-modifying anti-rheumatic drug (DMARD) extensively used in the management of psoriasis and psoriasis arthritis, lately approved for treating oral ulcerations in Behçets disease. Its advantageous side effect profile together with its uncomplicated follow-up and monitoring when compared to other DMARDs facilitates even a broad off-label prescribing. Here, the first case of laryngeal pseudotumor in a patient treated with apremilast for plaque psoriasis is presented.

Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la

1998 ◽  
Vol 4 (6) ◽  
pp. 487-489 ◽  
Author(s):  
David C Mohr ◽  
William Likosky ◽  
Arne C Boudewyn ◽  
Peter Marietta ◽  
Pat Dwyer ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Side Effect ◽  
Interferon Beta ◽  
Side Effect Profile ◽  
Patient Reported ◽  
Relationship Of ◽  
The Relationship

This study examines the course of patient-reported side effect during the first 4 months of treatment for multiple sclerosis (MS) with interferon beta-Ia (IFNβ-Ia), and the relationship of those side effects to discontinuation of medication. Flu-like symptoms, muscle aches and chills decreased over the first 2 months of treatment but did not change over the second 2 months. Loss of feeling or numbness, tingling and depression increased over 4 months, however these side effects were generally mild. Loss of feeling or numbness and tingling at 2 month follow-up were significantly related to discontinuation of IFNβ-Ia by 4 month follow-up.

scholarly journals Efficacy Of Pulse Therapy Of Oral Fluconazole In The Treatment Of Seborrheic Dermatitis

2012 ◽  
Vol 17 (2) ◽  
pp. 25-29 ◽  
Author(s):  
Mustafizur Rahman ◽  
Aref Rahman ◽  
Md Mostaque Mahmud ◽  
Samaresh Chandra Hazra ◽  
Md Mostaque Hassan Chowdhury
Keyword(s):  
Side Effect ◽  
Seborrheic Dermatitis ◽  
Positive Family History ◽  
Poor Response ◽  
Pulse Therapy ◽  
Oral Fluconazole ◽  
History Of ◽  
Good Improvement ◽  
Medical University

An interventional study was carried out for a period of total two years in the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. Total sixty five patients of seborrheic dermatitis were selected and were treated with oral fluconazole 150mg in a single dose per week for 4 weeks. Follow up were done at the end of 4th week and 8th week. Among the patients, 31-45 years age group was highest 44%, highest 54% males and 21(32%) had positive family history of seborrheic dermatitis. Regarding site of lesions, maximum patients of seborrheic dermatitis 92% had involvement of scalp; next 46% had involvement in the eyebrow. The study showed that the response was very good in 31.5 of cases, good response was found in 24.5% of cases, fair in 26% of cases and poor response was observed in 18.5% of cases. The study showed that 83% of study population was seen without clinical side-effect and only 17% were seen with side-effect(anorexia and dydpepsia) and it was showed that very good improvement 35% observed on the 1st follow up visit at the fourth week, 30% had good, 15% fair and poor improvement 20% respectively. On the 2nd follow up visit at the end of eight week, very good improvement was 39% cases; good, fair and poor improvement was 26%, 20% and 17% respectively. The results of this study indicate that fluconazole provides benefit for the therapy of seborrheic dermatitis. However, larger studies using different dosages and durations of therapy, fluconazole may provide a rationale for systemic use of fluconazole in seborrheic dermatitis. DOI: http://dx.doi.org/10.3329/jdnmch.v17i2.12212 J. Dhaka National Med. Coll. Hos. 2011; 17 (02): 25-29

scholarly journals Efficacy of Pulse Therapy of Oral Fluconazole in the Treatment of Seborrheic Dermatitis

2013 ◽  
Vol 24 (2) ◽  
pp. 66-69
Author(s):  
LI Khondker ◽  
MA Wahab ◽  
MSI Khan
Keyword(s):  
Family History ◽  
Side Effect ◽  
Seborrheic Dermatitis ◽  
Positive Family History ◽  
Poor Response ◽  
Pulse Therapy ◽  
Oral Fluconazole ◽  
Good Improvement ◽  
Medicine Today

An interventional study was carried out for a period of total two years in the department of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. Total sixty five patients of seborrheic dermatitis were selected and were treated with oral fluconazole 150mg in a single dose per week for 4 weeks. Follow up were done at the end of 4th week and 8th week. Among the patients, 31-45 years age group was highest 44%, highest 54% males and 21 (32%) had positive family history and 44 (68%) had negative family history of seborrheic dermatitis. Among the sixty five patients, mild form was 54%, moderate was 22% and severe was 12%. Highest patients of seborrheic dermatitis 51% had the duration of lesion 1 to 3 years and next 38% had the duration 4 to 6 years. Regarding site of lesions, maximum patients of seborrheic dermatitis 92% had involvement of scalp; next 46% had involvement in the eyebrow. The study showed that the response was very good in 31.5 of cases, good response was found in 24.5% of cases, fair in 26% of cases and poor response was observed in 18.5% of cases. The study showed that 83% of study population was seen without clinical side-effect and only 17% were seen with side-effect(anorexia and dydpepsia) and it was showed that very good improvement 35% observed on the 1st follow up visit at the fourth week, 30% had good, 15% fair and poor improvement 20% respectively. On the 2nd follow up visit at the end of eight week, very good improvement was 39% cases; good, fair and poor improvement was 26%, 20% and 17% respectively. The results of this study indicate that fluconazole provides benefit for the therapy of seborrheic dermatitis. However, larger studies using different dosages and durations of therapy, fluconazole may provide a rationale for systemic use of fluconazole in seborrheic dermatitis.DOI: http://dx.doi.org/10.3329/medtoday.v24i2.15009 Medicine Today 2012 Vol.24(2): 66-69

Valproic Acid:

1999 ◽  
Vol 16 (2) ◽  
pp. 130-136 ◽  
Author(s):  
Sayonara Beatriz Ranciaro Fagundes
Keyword(s):  
Health Care ◽  
Valproic Acid ◽  
Antiepileptic Drug ◽  
Detailed Analysis ◽  
Side Effect ◽  
Side Effect Profile ◽  
Care Givers

Clinical pharmacologists, neurologists, and all health care givers must consider the efficacy, safety, and side effect profile of a given antiepileptic drug when determining which drug is best for a given patient.The purpose of this study was to investigate valproic acid with a detailed analysis of the different reports.

Sign in / Sign up

Export Citation Format

Share Document